ANAmi Neuberger

Ami Neuberger

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ami Neuberger has a total of 83 co-authors. Here are the top co-authors by number of shared publications:

  • M. Paul

    Division of Infectious Diseases, Rambam Medical Centre, Haifa, Israel; Bruce Rappaport Faculty of Medicine, Technion Institute of Technology, Haifa, Israel

    6 shared publications
  • Eli Schwartz

    The Chaim Sheba Medical Center, Tel Hashomer & Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

    4 shared publications
  • B. Bishop

    Internal Medicine B, Rambam Medical Centre, Haifa, Israel

    2 shared publications
  • Dafna Yahav

    Infectious Diseases Unit, Sheba Medical Center, Ramat Gan, Israel

    2 shared publications
  • E Schwartz

    Sheba Medical Center, Geographic Medicine and Tropical Diseases, Ramat Gan, Israel

    2 shared publications
  • R. Bitterman

    Division of Infectious Diseases, Rambam Medical Centre, Haifa, Israel

    2 shared publications

Latest Publications

  • Open Access

    Empirical Anthelmintic Therapy for Patients with Eosinophilia in Nepal: A Prospective Cohort Study

    by Karawan Badarni, Prithuja Poudyal, Sudeep Shrestha, Surendra Kumar Madhup, Mohje Azzam, Ami Neuberger, Niv Zmora, Yael Paran, Yuri Gorelik, Eli Schwartz

    Eosinophilia is common in low-resource countries and usually implies helminthiasis. Since helminthiasis is a common cause of eosinophilia and its diagnosis is cumbersome, we hypothesized that broad-spectrum anthelmintic therapy may decrease the eosinophil count and eventually cure helminthiasis, whether microbiologic diagnosis is established or not. We recruited patients with eosinophilia aged 5 years and older who presented to Dhulikhel hospital, Nepal. Patients were treated with albendazole and ivermectin. A stool sample for microscopy was obtained. Of a total of 113 patients, 106 had a follow-up visit and 56 were classified as responders to treatment (defined as a decrease in eosinophil count to below 500 cells/µL, or an absolute decrease of more than 1000 cells/µL). For all patients, we found an absolute decrease in the eosinophil count and for the responding group (more than 50% of the whole cohort), the eosinophil count decreased substantially. All stool samples were negative. The reason for a lack of response in the remaining patients is unclear. In order to ascertain whether eosinophilia should be an indication for anthelmintic treatment, a randomized controlled study of empirical treatment after a thorough microbiologic workup is needed.


  • From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2?

    by S Rakedzon, A Neuberger, A J Domb, N Petersiel, E Schwartz

    Background: Nearly a year into the COVID-19 pandemic, we still lack effective anti-SARS-CoV-2 drugs with substantial impact on mortality rates except for dexamethasone. As the search for effective antiviral agents continues, we aimed to review data on the potential of repurposing antiparasitic drugs against viruses in general, with an emphasis on coronaviruses. Methods: We performed a review by screening in vitro and in vivo studies that assessed the antiviral activity of several antiparasitic agents: chloroquine, hydroxychloroquine (HCQ), mefloquine, artemisinins, ivermectin, nitazoxanide (NTZ), niclosamide, atovaquone and albendazole. Results: For HCQ and chloroquine we found ample in vitro evidence of antiviral activity. Cohort studies that assessed the use of HCQ for COVID-19 reported conflicting results, but randomized controlled trials (RCTs) demonstrated no effect on mortality rates and no substantial clinical benefits of HCQ used either for prevention or treatment of COVID-19. We found two clinical studies of artemisinins and two studies of NTZ for treatment of viruses other than COVID-19, all of which showed mixed results. Ivermectin was evaluated in one RCT and few observational studies, demonstrating conflicting results. As the level of evidence of these data is low, the efficacy of ivermectin against COVID-19 remains to be proven. For chloroquine, HCQ, mefloquine, artemisinins, ivermectin, NTZ and niclosamide, we found in vitro studies showing some effects against a wide array of viruses. We found no relevant studies for atovaquone and albendazole. Conclusions: As the search for an effective drug active against SARS-CoV-2 continues, we argue that pre-clinical research of possible antiviral effects of compounds that could have antiviral activity should be conducted. Clinical studies should be conducted when sufficient in vitro evidence exists, and drugs should be introduced into widespread clinical use only after being rigorously tested in RCTs. Such a search may prove beneficial in this pandemic or in outbreaks yet to come.


  • Open Access

    Pathogens isolated in respiratory tract samples of recently hospitalized patients: Implications for primary care physicians

    by Oryan Henig, Anat Reiner Benaim, Ami Neuberger

    Background. Little is known about the etiology of community-acquired lower respiratory tract infections (CA-LRTI), and treatment is largely empirical. We aimed to provide clinicians with microbiologic data of the more severe cases, i.e. those that result in hospital admission.Methods. A retrospective cohort study was conducted at a tertiary care hospital in Haifa, Israel. Consecutive respiratory tract samples obtained from admitted patients older than 12 years between 2014 and 2020 were included. Pathogen distribution and drug susceptibility were described, and factors associated with 14 day mortality rates were analyzed using a multivariable logistic regression with a stepwise model reduction.Results. A total of 1,395; 2,212; and 2,760 samples were included in the community-acquired LRTI with no healthcare exposure, community-acquired LRTI with recent healthcare exposure, and LRTI diagnosed 48 hours to 7 days within hospital admission LRTI groups, respectively. Gram negative bacteria were the most common bacteria isolated. Streptococcus pneumoniae was over represented in patients admitted to the intensive care unit in the first two study groups (accounting for 20% and 10.1% of patients admitted to the ICU versus 12.6% and 6.4% of patients in the entire cohort, p < 0.001). Streptococcus pneumoniae was susceptible to penicillin in around 50% of cases; to erythromycin in 65% of cases; and to fluoroquinolones and 3rd generation cephalosporins in more than 95% of cases. Twenty-five percent of other typical community pathogens were resistant to ampicillin. Susceptibility of Gram negative bacteria to penicillins with and without a β-lactamase inhibitor and to second generation cephalosporins was lower than 50%. In the multivariable analysis, factors that were associated with increased mortality in the entire cohort were: age, admission to an ICU or surgical department, healthcare-associated infections, and infections with gram negative bacteria, Staphylococcus aureus, and Stenotrophomonas or Acinetobacter baummannii. Conclusions. Our data shows that gram negative bacteria are the most common pathogens causing LRTI. Typical community acquired pathogens are proportionally more common in younger patients, although the vast majority occur in elderly patients. The susceptibility pattern of these pathogens suggests that for high-risk patients the choice of oral antibiotics is limited.

  • Case Report: Histoplasmosis: First Autochthonous Case from Israel

    by Adi Elias, Yael Fisher, Yuval Geffen, Ami Neuberger, Nabil Faranesh, Raid Dalal, Khaldun Abu Saleh, Suleiman Zaaroura

    We present an autochthonous Histoplasma infection in Israel. The patient presented with hoarseness and weight loss. Pathology findings and molecular tests confirmed the diagnosis, and the patient responded to antifungal therapy. Because the patient had an atypical presentation of histoplasmosis, it is likely that other more typical cases have gone unreported. To our knowledge, no other cases have been previously reported from Israel or the Middle East region.


  • Duration of viral shedding and factors associated with prolonged shedding among inpatients with influenza treated with oseltamivir: a prospective cohort study

    by J. Khoury, M. Szwarcwort, Z. Kra-Oz, M. Saffuri, K. Seh, T. Yahalomi, E. Braun, Z. S. Azzam, M. Paul, A. Neuberger

    The purpose of this study was to determine the rate of decline in the diagnostic yield of influenza PCR assay after oseltamivir administration, and to identify risk factors for prolonged shedding. This was a prospective observational study. We included adult inpatients with clinical signs of influenza during the influenza seasons 2015 and 2016, who had positive influenza PCR tests and who were treated with oseltamivir. Clinical follow-up and repeat PCR testing were performed on days 2, 4 and 6 after the first positive test. We defined prolonged shedders as patients who still required hospitalization and had a positive PCR assay on day 4. Risk factors for prolonged shedding were assessed in univariate and multivariate analyses. A total of 215 patients were included in our study. The median age was 64 years and 49.3% were men. The main influenza type was H1N1 (50.1%). Rates of PCR positivity among evaluable patients on days 2, 4 and 6 were 142/215 (66%), 50/78 (64.1%) and 20/30 (66.6%), respectively. Independent risk factors for prolonged shedding (50 patients) included hypoxemia [odds ratio (OR) 2.55, 95% confidence interval (1.3–5.1)] and lower diastolic blood pressure [OR 0.94, 95% CI (0.92–0.97)] on admission. Negative PCR tests taken more than 48 h after initiation of treatment had low diagnostic yield. More severe disease, manifested by hypoxemia and lower blood pressure, is associated with prolonged shedding on oseltamivir treatment.


  • Management of post-neurosurgical meningitis: narrative review

    by K. Hussein, R. Bitterman, B. Shofty, M. Paul, A. Neuberger


  • Pros and cons of circumcision: an evidence-based overview

    by B. Friedman, J. Khoury, N. Petersiel, T. Yahalomi, M. Paul, A. Neuberger


  • Risk factors associated with death or neurological deterioration among patients with Gram-negative postneurosurgical meningitis

    by A. Neuberger, B. Shofty, B. Bishop, M.E. Naffaa, T. Binawi, T. Babich, Z.H. Rappaport, M. Zaaroor, G. Sviri, D. Yahav, et al.


  • Open Access

    Dengue fever among Israeli expatriates in Delhi, 2015: implications for dengue incidence in Delhi, India

    by Ami Neuberger, Avigail Turgeman, Yaniv Lustig, Eli Schwartz

    We present the data of 13 dengue cases diagnosed between 1 August and 15 September 2015 among 240 Israeli expatriates residing in Delhi. Attack rates were similar between adults (6/128, 4.7%) and children (7/112, 6.3%). dengue virus (DENV-2) was identified in two and DENV-1 in one dengue-seropositive sample. Another febrile patient was diagnosed with chikungunya virus infection. The reported incidence of dengue fever among people living in Delhi was lower than 0.1% as of September 2015. Based on our results, we hypothesize that the incidence of dengue fever in Delhi is grossly underestimated.